AcouSort signs three more AcouWash system contracts
Idag, 10:00
AcouSort AB today announced it has signed three separate contracts around the AcouWash benchtop system, including an order from a research group at the University of Wisconsin-Madison.
“We are very pleased with the interest shown by both academia and the industry for our AcouWash systems,” said AcouSort’s CEO Dr. Torsten Freltoft.
The AcouWash system ordered by the researchers at the University of Wisconsin-Madison will be used both in the group’s research within the area of radiology, as well as for applications related to cell isolation for cytometry applications. The system will be delivered shortly and will be used to simplify the lab’s sample preparation workflows that today contain repeated centrifugation cycles.
In addition, two new lease contracts on AcouWash systems have recently been signed; one to a Flow cytometry core facility at an Italian research institute and the other to a Korean biotech company. If the lease periods go well and the AcouWash fulfils the user needs, the leases may be prolonged or turn into acquisitions of the systems.
“Being able to lease out the AcouWash systems have previously been shown to be a good way of building collaborations, and we are looking forward to the results from these two leases,” said Dr. Freltoft.
FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Tapper Partners AB.
Attachments
AcouSort signs three more AcouWash system contracts
Ämnen i artikeln
AcouSort signs three more AcouWash system contracts
Idag, 10:00
AcouSort AB today announced it has signed three separate contracts around the AcouWash benchtop system, including an order from a research group at the University of Wisconsin-Madison.
“We are very pleased with the interest shown by both academia and the industry for our AcouWash systems,” said AcouSort’s CEO Dr. Torsten Freltoft.
The AcouWash system ordered by the researchers at the University of Wisconsin-Madison will be used both in the group’s research within the area of radiology, as well as for applications related to cell isolation for cytometry applications. The system will be delivered shortly and will be used to simplify the lab’s sample preparation workflows that today contain repeated centrifugation cycles.
In addition, two new lease contracts on AcouWash systems have recently been signed; one to a Flow cytometry core facility at an Italian research institute and the other to a Korean biotech company. If the lease periods go well and the AcouWash fulfils the user needs, the leases may be prolonged or turn into acquisitions of the systems.
“Being able to lease out the AcouWash systems have previously been shown to be a good way of building collaborations, and we are looking forward to the results from these two leases,” said Dr. Freltoft.
FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Tapper Partners AB.
Attachments
AcouSort signs three more AcouWash system contracts
Ämnen i artikeln
Aktierekar
Försvarsaktier
Analys
Aktierekar
Försvarsaktier
Mest läst
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
